CJC-1295 Compounding Legal Status: What the FDA Actually Says

What Is CJC-1295 and How Does It Differ from Native GHRH?

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH). It consists of the first 29 amino acids of GHRH fused to a Drug Affinity Complex (DAC) lysine moiety that covalently binds albumin, extending the plasma half-life from minutes to approximately 6-8 days [1]. The underlying peptide sequence, modified GRF 1-29, is sometimes sold separately without the DAC attachment under the informal name "Mod GRF 1-29," though the two are often conflated in clinical and marketing contexts.

Mechanism of Action

After subcutaneous injection, CJC-1295 binds pituitary GHRH receptors and stimulates pulsatile release of endogenous growth hormone (GH) [1]. Because it does not directly supply GH, it preserves some degree of physiologic feedback regulation via somatostatin. This distinguishes it mechanistically from recombinant human GH (rhGH) products such as somatropin, all of which carry FDA approval under specific labeled indications [2].

The 2006 Teichman Trial

The primary human pharmacokinetic and pharmacodynamic data come from a single dose-escalation study by Teichman et al., published in the Journal of Clinical Endocrinology and Metabolism in 2006 [1]. That trial enrolled 65 healthy adults across multiple cohorts. A single subcutaneous injection of CJC-1295 at doses ranging from 30 mcg/kg to 120 mcg/kg produced dose-dependent increases in mean plasma GH (2- to 10-fold above baseline) and IGF-1 (up to 1.5- to 3-fold above baseline) that persisted for 6 days or longer [1]. The authors concluded the extended half-life was consistent with albumin binding via the DAC moiety. No Phase 2 or Phase 3 randomized controlled trials evaluating clinical outcomes (body composition, fracture risk, cardiovascular endpoints) in any patient population have been published in indexed, peer-reviewed literature.

Why the Trial Data Are Insufficient for FDA Approval

FDA approval under 21 U.S.C. § 355 requires demonstration of safety and efficacy through adequate and well-controlled trials [3]. A single Phase 1 pharmacokinetic study in 65 healthy subjects does not meet that standard. No sponsor submitted a New Drug Application (NDA) or Biologics License Application (BLA) for CJC-1295, and the compound does not appear in the Drugs@FDA database as an approved product [4].

CJC-1295's FDA Regulatory Classification

CJC-1295 is an unapproved new drug. It has never been the subject of an approved NDA or BLA [4]. Its regulatory history inside the U.S. Runs primarily through the compounding framework.

The 503A and 503B Compounding Frameworks

Under the Drug Quality and Security Act of 2013, pharmacies may compound drugs from bulk substances if those substances appear on an FDA-maintained "503A bulks list" or meet specific criteria [5]. Outsourcing facilities (503B) operate under a parallel but distinct list. The FDA evaluates candidate bulk substances for clinical need, safety, and the availability of approved alternatives before placing them on either the positive (may compound) or negative (may not compound) lists [5].

CJC-1295 on the Negative List

The FDA nominated CJC-1295 for evaluation as a 503A bulk compounding substance. Following review, the agency placed it on the list of bulk drug substances that may not be used in compounding under section 503A [6]. The FDA's reasoning centered on the lack of adequate safety and efficacy data, the absence of a documented clinical need that could not be met by approved alternatives, and concerns about the pharmacologic class. That placement means 503A pharmacies may not compound CJC-1295 for individual patient prescriptions regardless of prescriber intent or patient preference [6].

503B Outsourcing Facilities

503B outsourcing facilities, which produce larger batches for hospital and clinic use, operate under a separate but related regulatory pathway. CJC-1295 does not appear on the 503B bulks list maintained by the FDA [7]. Absent an explicit nomination and positive determination, 503B facilities may not include CJC-1295 in their compounded preparations. Facilities that have continued producing CJC-1295 after the negative list determination face FDA enforcement actions including warning letters and injunctions [8].

Enforcement Actions

The FDA has issued warning letters to compounding pharmacies and online distributors selling peptides including CJC-1295 as research chemicals or for "laboratory use only" [8]. These letters cite violations of the Federal Food, Drug, and Cosmetic Act for manufacturing unapproved new drugs, misbranding, and failure to comply with Current Good Manufacturing Practice (CGMP) regulations. Prescribers who order from non-compliant pharmacies may also face scrutiny from state medical boards.

What the CJC-1295 "Label" Actually Means

Patients frequently search for the "CJC-1295 label," expecting a package insert analogous to those for FDA-approved drugs. No such label exists for a legally marketed product.

Research Chemical Certificates of Analysis

What circulates online under the name "CJC-1295 label" is typically a certificate of analysis (COA) from a chemical supplier or a product information sheet from a compounding pharmacy. These documents are not FDA-reviewed labels. They carry no regulatory weight regarding dosing, indications, contraindications, or adverse event reporting [4]. The FDA does not review or approve COAs from compounding pharmacies or research chemical vendors.

Compounding Pharmacy Worksheets

Some 503A pharmacies that have continued compounding CJC-1295 despite the negative list determination produce internal worksheets listing concentration, diluent, route of administration, and storage requirements. These worksheets are generated entirely by the pharmacy's internal quality staff. They do not reflect FDA-approved dosing. Recommended doses in circulation (typically 100-300 mcg subcutaneously two to three times per week) are extrapolated from the Teichman 2006 study or from clinical experience at anti-aging and wellness clinics, not from approved labeling [1].

Comparison with Sermorelin Labeling

Sermorelin acetate (GHRH 1-29 without the DAC moiety) received FDA approval in 1997 under the brand name Geref for treatment of idiopathic growth hormone deficiency in children. Although Geref was later voluntarily withdrawn from the market by the manufacturer, sermorelin remains on the 503A positive bulks list and may be lawfully compounded [9]. Compounded sermorelin carries prescribing information derived from the original Geref NDA, giving it a more substantial evidence base than CJC-1295.

CJC-1295 Safety Data: What Is and Is Not Known

The safety profile of CJC-1295 in humans is thin. One published clinical study with 65 subjects, no long-term follow-up, and no randomized controlled trial data represent the entirety of indexed human safety evidence.

Adverse Events Reported in Teichman 2006

In the Teichman 2006 study, adverse events were generally mild and transient [1]. Reported effects included headache, flushing, and injection-site reactions. No serious adverse events were reported at doses up to 120 mcg/kg. The trial duration was short and the population was healthy adults, so the data do not address chronic use, older populations, individuals with obesity, or those with metabolic disease.

Theoretical Risks from GH Axis Stimulation

Sustained GH and IGF-1 elevation carries theoretical risks supported by data from approved GH therapies. The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults notes that supraphysiologic GH exposure is associated with fluid retention, arthralgias, carpal tunnel syndrome, and insulin resistance [10]. Acromegaly, caused by chronic excess GH, is associated with increased cardiovascular mortality [11]. Whether the degree of GH stimulation produced by CJC-1295 is sufficient to produce these effects with chronic use is unknown because no long-term human data exist.

IGF-1 and Cancer Risk

The relationship between elevated IGF-1 and cancer risk has been studied extensively. A 2004 meta-analysis in the Journal of the National Cancer Institute found that higher circulating IGF-1 levels were associated with modestly increased risk of prostate and premenopausal breast cancer [12]. The FDA cited concern about this relationship in its review of several GHRH analogues. This does not establish that therapeutic use of CJC-1295 causes cancer, but it is a pharmacologic consideration that no long-term CJC-1295 trial has addressed.

Drug Interactions and Contraindications

No formal drug interaction studies for CJC-1295 have been published in indexed literature. Extrapolating from the GH axis pharmacology, concurrent use with insulin or insulin secretagogues may increase hypoglycemia risk due to GH-mediated insulin resistance [10]. Use in patients with active malignancy is generally contraindicated for all GH-axis stimulating agents based on the Endocrine Society guideline [10]. Pregnancy and lactation safety data for CJC-1295 are entirely absent.

Approved Alternatives and Clinical Context

For patients and prescribers interested in GH-axis support through a legally available compound, several options exist within the current regulatory framework.

Sermorelin

Sermorelin (compounded) remains the most direct structural analogue to CJC-1295 that a 503A pharmacy may lawfully dispense [9]. It shares the modified GRF 1-29 amino acid sequence but lacks the DAC extension, so its half-life is shorter and dosing is typically daily rather than twice or three times weekly.

Tesamorelin

Tesamorelin (Egrifta SV) is an FDA-approved GHRH analogue with an indication for HIV-associated lipodystrophy [13]. Its approval is supported by two Phase 3 randomized controlled trials. Off-label use outside that indication involves the same prescriber risk considerations that apply to any unapproved use, but the drug itself has passed the FDA approval threshold.

Ipamorelin

Ipamorelin is a GH secretagogue peptide that acts via the ghrelin receptor rather than the GHRH receptor. Its 503A compoundable status has also been under FDA review. Prescribers should verify current status with their compounding pharmacy before prescribing, as the FDA's bulks list is updated periodically [6].

The table below summarizes the regulatory standing of GHRH-class and GH-secretagogue peptides as of the date this article was last reviewed. Prescribers should confirm current status at the FDA's website before writing new prescriptions, because the bulks list is subject to revision.

| Compound | FDA-Approved Product | 503A Compoundable | 503B Compoundable | |---|---|---|---| | Somatropin (rhGH) | Yes (multiple brands) | No (approved drug available) | No | | Sermorelin | No (Geref withdrawn) | Yes | Under review | | Tesamorelin | Yes (Egrifta SV) | No | No | | CJC-1295 | No | No (negative list) | No | | Ipamorelin | No | Under active review | No |

What Prescribers Must Do Before Writing a CJC-1295 Prescription

Writing a prescription for CJC-1295 from a 503A compounding pharmacy currently puts both the prescriber and pharmacy outside FDA regulatory compliance.

Verify Pharmacy Status

Prescribers should confirm that the pharmacy holds a valid state license and, if applicable, an FDA outsourcing facility registration. They should ask the pharmacy to provide documentation of which bulk substances it compounds under which regulatory authority. A pharmacy that claims it may lawfully compound CJC-1295 under 503A should be asked to provide the specific FDA determination authorizing that use. As of the date this article was last reviewed, no such positive determination exists [6].

Document Clinical Rationale

If a prescriber believes a patient has a medical need for GH-axis stimulation, that need should be documented with objective laboratory findings including morning serum GH, IGF-1 with age- and sex-specific reference ranges, and, where indicated, GH stimulation testing per Endocrine Society guidelines [10]. Documentation supports both clinical decision-making and any future regulatory review of the prescription.

Informed Consent

Patients receiving any unapproved compound should receive written informed consent explaining the absence of FDA approval, the limited human safety data, the theoretical risks associated with GH-axis stimulation, and the current legal status of the compound. The FDA's MedWatch program at fda.gov provides a reporting pathway for adverse events from compounded drugs [14].

Adverse Event Reporting

Because CJC-1295 is not an approved drug, adverse events are not captured in a formal pharmacovigilance database. Prescribers who observe adverse events should report them through MedWatch [14]. This reporting is voluntary for practitioners but supports the FDA's ability to detect safety signals from unapproved compounds.

Current Enforcement Climate

The FDA has increased enforcement activity against peptide compounding since 2023. Warning letters have cited unapproved new drug status, failure to comply with CGMP, and misbranding for peptides including BPC-157, TB-500, and CJC-1295 [8]. The agency's position, articulated in multiple warning letters, is that these substances do not meet the criteria for lawful compounding under either 503A or 503B because they lack the requisite safety and efficacy data and have not been placed on the appropriate positive bulks list.

State pharmacy boards in California, Florida, and Texas have issued parallel guidance restricting the dispensing of certain peptides from in-state compounding pharmacies. Prescribers operating in those states face dual federal and state regulatory risk when ordering CJC-1295.

The practical effect for telehealth prescribers is that a prescription for compounded CJC-1295, even when written by a licensed physician for an identifiable patient with a documented clinical rationale, may not be lawfully filled by any 503A or 503B pharmacy in the United States under current regulations [5][6].